When IL-6 receptor inhibitors are infused into RA patients with active disease, their serum levels of IL-6 increase greatly and rapidly due to the continued production of IL-6 by active inflammation and the capping of the IL-6 receptor by IL-6 inhibitor [17]. The gene discussed is IL6; the disease is rheumatoid arthritis.